A.JohnstonMSc, PhD, DipStat, CSci, FBPharmacolS, FRCPath
Responsible for Technical Operations and Therapeutic Development. Medical Fellow of the British Pharmacological Society, the Royal College of Pathologists and the Royal Statistical Society.
Professor Johnston has over 30 years experience in the measurement of drugs as a guide to therapy.He has published over two hundred articles in peer-reviewed journals. He is a frequent speaker on a variety of issues relating to pharmacokinetics and dynamics and to drug quality and patient outcomes. His research interests are in clinical trial design and statistical data analysis, modelling pharmacokinetics and pharmacodynamics, and in the optimal use of drugs with particular reference to immunosuppressive, cardiovascular, analgesic and anti-cancer drugs.
Professor Johnston contributed to and written expert reports for submission to the National Institute for Clinical Excellence (NICE) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the European Medicine Evaluation Agency (EMEA), the US Food and Drugs Administration (FDA), Health Canada, the South African Medicines Control Council (MCC) and other international drug regulatory authorities.
Responsible for Technical Operations and Therapeutic Development. Medical Fellow of the British Pharmacological Society, the Royal College of Pathologists and the Royal Statistical Society.
Professor Johnston has over 30 years experience in the measurement of drugs as a guide to therapy.He has published over two hundred articles in peer-reviewed journals. He is a frequent speaker on a variety of issues relating to pharmacokinetics and dynamics and to drug quality and patient outcomes. His research interests are in clinical trial design and statistical data analysis, modelling pharmacokinetics and pharmacodynamics, and in the optimal use of drugs with particular reference to immunosuppressive, cardiovascular, analgesic and anti-cancer drugs.
Professor Johnston contributed to and written expert reports for submission to the National Institute for Clinical Excellence (NICE) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the European Medicine Evaluation Agency (EMEA), the US Food and Drugs Administration (FDA), Health Canada, the South African Medicines Control Council (MCC) and other international drug regulatory authorities.
